Clinical trials: Sirolimus, completed
Advanced Cancer, Solid Tumor
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with either everolimus or temsirolimus. The safety of these drug combinations will also be studied.
- Trial name
- NCT01596140
- Testing
- Vemurafenib, Everolimus, Temsirolimus
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Leukemia, Myelodysplastic Syndromes
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
This is a single-arm, phase I/II, study of PTCy/sirolimus plus VIC-1911 to prevent GVHD and relapse after Allogeneic Hematopoietic Cell Transplantation (alloHCT).
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Lymphoma
- Trial name
- NCT05120570
- Testing
- VIC- 1911
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Kidney Transplantation
Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients
The purpose of this study was to determine whether an early Calcineurin Inhibitor (CNI) to everolimus conversion at 10-14 weeks post transplantation improves renal allograft function without compromising efficacy compared to…
- Trial name
- ELEVATE (NCT01114529)
- Testing
- Everolimus, Prograf or Neoral
- Where
- 77 sites in Argentina, Australia and 19 more
- Volunteers
- 828 people
- Sponsor
- Novartis Pharmaceuticals
Renal Artery Stenosis
A Comparison of Coated and Uncoated Stents in Renal Artery Treatment.
The primary objective of this study is to compare the safety and performance of the Palmaz Genesis™ balloon expandable stent, with or without sirolimus coating in the treatment of renal artery stenosis, measured at 6 months…
- Trial name
- GREAT (NCT00235157)
- Testing
- Sirolimus-eluting Palmaz Genesis peripheral stent
- Where
- 3 sites in France, Germany and 1 more
- Volunteers
- 105 people
- Sponsor
- Cordis US Corp.
Ischemic Heart Disease
Randomized Study Comparing Endeavor With Cypher Stents (PROTECT)
The PROTECT TRIAL is a randomized stent trial with 8800 patients in approximately 200 hospitals, which is designed to evaluate whether the Endeavor stent PROTECTS against late stent thrombosis resulting in less deaths and…
- Trial name
- PROTECT (NCT00476957)
- Testing
- Stent
- Where
- Netherlands
- Volunteers
- 8,709 people
- Sponsor
- Medtronic Vascular
Type 2 Diabetes, Coronary Heart Disease
Trial on Safety & Performance of TAXUS Element vs. XIENCE Prime Stent in Treatment of Coronary Lesion in Diabetics
The TUXEDO-India is a prospective, single blind, multi-center randomized clinical trial to assess the TAXUS Element™ in a consecutive population of diabetic patients with coronary artery disease undergoing coronary…
- Trial name
- Tuxedo (NCT03125772)
- Testing
- TAXUS Element™ Paclitaxel-Eluting Stent System, Xience PRIME Everolimus-Eluting Stent System
- Where
- India
- Volunteers
- 1,830 people
- Sponsor
- Fortis Escorts Heart Institute
Diabetic Macular Edema, Diabetic Retinopathy
Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
The purpose of this study is to determine the safety and tolerability of MS-R001 at escalating doses in patients with diabetic macular edema secondary to diabetic retinopathy
- Trial name
- NCT00401115
- Testing
- MS-R001 (rapamycin)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Santen Inc.
Recurrent Endometrial Carcinoma
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial is studying the side effects of giving bevacizumab together with temsirolimus and to see how well it works in treating patients with recurrent or persistent endometrial cancer.
- Trial name
- NCT00723255
- Testing
- bevacizumab, temsirolimus
- Where
- 41 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01164176
- Testing
- everolimus, laboratory biomarker analysis
- Where
- 7 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation
This is a phase I single center dose escalation study with an extension at the best available dose to determine the tolerability of inducible regulatory T cells (iTregs) when given to adult patients undergoing non-myeloablative…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin Lymphoma
- Trial name
- NCT01634217
- Testing
- iTreg
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lymphoma
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
This is an open-label, randomized trial in relapsed refractory subjects with mantle cell lymphoma (MCL).
- Trial name
- OPTIMAL (NCT00117598)
- Testing
- Temsirolimus (CCI-779), Investigator's choice
- Where
- 73 sites in United States, Argentina and 16 more
- Volunteers
- 169 people
- Sponsor
- Pfizer
Graft Rejection, Kidney Failure
Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients
The purpose of the study is to determine the effect of conversion from calcineurin inhibitor based therapy to Rapamune based therapy in patients with mild to moderate renal insufficiency.
- Conditions
- Graft Rejection, Kidney Failure, Kidney Transplantation
- Trial name
- NCT00273871
- Testing
- Cyclosporin or tacrolimus
- Volunteers
- 190 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Genital Neoplasms, Female
A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
The aim of the trial is to determine the recommended phase II dose of weekly intravenous topotecan in combination with a fixed dose (25 mg or 15 mg) of weekly intravenous temsirolimus in patients with and without prior pelvic…
- Trial name
- NCT00523432
- Testing
- Topotecan, CCI-779 (temsirolimus)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Chicago
Diabetes Mellitus, Type 1
Minimal Islet Transplant at Diabetes Onset
This is a prospective phase 2, single-arm, mono-center pilot study. It has been designed to investigate whether giving the combination therapy consisting of minimal islet transplantation (1500 EIQ/Kg body weight), Thymoglobulin®…
- Trial name
- MITO (NCT02505893)
- Testing
- Human pancreatic islet, ATG, Pegylated G-CSF
- Where
- Italy
- Volunteers
- 6 people
- Sponsor
- Ospedale San Raffaele
Healthy
Bioavailability Study of Sirolimus Tablets 2 mg Under Fasting Condition
This study is to assess the Sirolimus Tablets 2 mg of Dr. Reddy's Laboratories Limited, India and Rapamune® (Sirolimus) tablets 2 mg of Wyeth Laboratories, Philadelphia in healthy, adult,human subjects under Fasting conditions.
- Trial name
- NCT02296749
- Testing
- Sirolimus
- Where
- India
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Coronary Restenosis, Coronary Thrombosis
OCT Evaluation of Healing of COMBO Stent
All subjects requiring percutaneous coronary intervention (PCI) and stenting are eligible to participate in the study. Restudy coronary angiogram with Optical Coherence Tomography (OCT) would be performed between 1 to 5 months at…
- Trial name
- EGO-COMBO (NCT01274234)
- Testing
- COMBO Stent (OrbusNeich Medical, Fort Lauderdale, Florida)
- Where
- Hong Kong
- Volunteers
- 61 people
- Sponsor
- Prof. Stephen Lee
Graft Versus Host Disease
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
The clinical trial is a Phase 1/2a, open-label, multi-center, dose-escalation study to evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients undergoing AHSCT, with radiation or non-radiation…
- Trial name
- NCT01379209
- Testing
- RGI-2001, Calcineurin Inhibitors, Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- 6 sites in United States
- Volunteers
- 68 people
- Sponsor
- Regimmune Corporation
Hormone Receptor Positive Breast Cancer
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
The purpose of this study was to assess the efficacy and safety of first-line treatment with everolimus plus letrozole in postmenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2…
- Trial name
- BOLERO-4 (NCT01698918)
- Testing
- Everolimus, Letrozole, Exemestane
- Where
- 52 sites in United States, Argentina and 11 more
- Volunteers
- 202 people
- Sponsor
- Novartis Pharmaceuticals
Non-small-cell Lung Carcinoma
Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
This study will evaluate the efficacy and safety of everolimus treatment of patients with advanced NSCLC. The rationale for investigating everolimus in advanced NSCLC previously treated with chemotherapy or chemotherapy plus EGFR…
- Trial name
- NCT00124280
- Testing
- RAD001
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- Novartis Pharmaceuticals
Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
Epidermolysis bullosa (EB) simplex is a rare orphan disease caused by a mutation in DNA leading to abnormal dominant keratins in the skin.
- Conditions
- Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner, Weber-Cockayne Syndrome
- Trial name
- NCT02960997
- Testing
- Sirolimus, 2%, Vehicle
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.